Cai Linrui, Song Yanlin, Zhao Xia
Department of Gynecology and Obstetrics, Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, Sichuan University.
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, PR China.
Medicine (Baltimore). 2020 Apr;99(14):e19638. doi: 10.1097/MD.0000000000019638.
This study aimed to systematically assess the prognostic value of lymphocyte monocyte ratio (LMR) in patients with ovarian cancer through performing a meta-analysis.
Web of Science, PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure databases were searched for potentially eligible studies. The baseline characteristics and relevant data were extracted. Hazard ratios with 95% confidence intervals (CIs) were combined to assess the prognostic value of LMR in patients with ovarian cancer.
Nine studies enrolling 2809 patients were included. The pooled hazard ratios of lower LMR for overall survival and progression free survival in patients with ovarian cancer were 1.71 (95% CI, 1.40-2.09) and 1.68 (95% CI, 1.49-1.88), respectively. Subgroup analysis and sensitivity analysis were also performed. No significant publication bias was found.
Our results suggested that lower LMR was associated with poorer overall survival and progression free survival in patients with ovarian cancer. The findings may assist prognosis evaluation and future research on therapies based on modulating host immune response in ovarian cancer.
本研究旨在通过进行一项荟萃分析，系统评估淋巴细胞单核细胞比率（LMR）在卵巢癌患者中的预后价值。
检索科学网、PubMed、EMBASE、Cochrane图书馆和中国知网数据库，以查找潜在符合条件的研究。提取基线特征和相关数据。合并具有95%置信区间（CI）的风险比，以评估LMR在卵巢癌患者中的预后价值。
纳入9项研究，共2809例患者。卵巢癌患者中，低LMR对总生存期和无进展生存期的合并风险比分别为1.71（95%CI，1.40 - 2.09）和1.68（95%CI，1.49 - 1.88）。还进行了亚组分析和敏感性分析。未发现明显的发表偏倚。
我们的结果表明，低LMR与卵巢癌患者较差的总生存期和无进展生存期相关。这些发现可能有助于卵巢癌的预后评估以及未来基于调节宿主免疫反应的治疗研究。
